Xiao-E Yan

505 total citations
10 papers, 321 citations indexed

About

Xiao-E Yan is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Xiao-E Yan has authored 10 papers receiving a total of 321 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 5 papers in Molecular Biology and 4 papers in Oncology. Recurrent topics in Xiao-E Yan's work include Lung Cancer Treatments and Mutations (7 papers), Cancer therapeutics and mechanisms (5 papers) and HER2/EGFR in Cancer Research (4 papers). Xiao-E Yan is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Cancer therapeutics and mechanisms (5 papers) and HER2/EGFR in Cancer Research (4 papers). Xiao-E Yan collaborates with scholars based in China, United States and Norway. Xiao-E Yan's co-authors include Cai‐Hong Yun, Peng Zhao, Ling Liang, Sujie Zhu, Hwan Geun Choi, Yuxin Yin, Xin Huang, David E. Shaw, Je-Luen Li and Yibing Shan and has published in prestigious journals such as Biochemical and Biophysical Research Communications, Journal of Medicinal Chemistry and European Journal of Medicinal Chemistry.

In The Last Decade

Xiao-E Yan

9 papers receiving 317 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiao-E Yan China 9 173 158 139 117 37 10 321
Stefanie Heynck Germany 6 228 1.3× 285 1.8× 249 1.8× 95 0.8× 28 0.8× 6 418
Tanya Ahmad United Kingdom 4 152 0.9× 93 0.6× 91 0.7× 32 0.3× 25 0.7× 10 262
Marina Keul Germany 9 211 1.2× 123 0.8× 110 0.8× 144 1.2× 30 0.8× 16 307
Hiromi Tanimura United States 8 205 1.2× 136 0.9× 148 1.1× 42 0.4× 20 0.5× 9 353
Anna Kohlmann United States 7 161 0.9× 76 0.5× 40 0.3× 59 0.5× 31 0.8× 10 300
Donna-Michelle Smith United Kingdom 9 151 0.9× 100 0.6× 213 1.5× 34 0.3× 28 0.8× 12 363
Stephen Wang United States 3 203 1.2× 196 1.2× 200 1.4× 52 0.4× 20 0.5× 3 321
Michael Grondine United States 8 421 2.4× 67 0.4× 265 1.9× 39 0.3× 25 0.7× 14 544
Edward J. Lewis United Kingdom 5 223 1.3× 77 0.5× 150 1.1× 46 0.4× 49 1.3× 5 360
Michael Juchum Germany 7 262 1.5× 187 1.2× 146 1.1× 150 1.3× 27 0.7× 10 376

Countries citing papers authored by Xiao-E Yan

Since Specialization
Citations

This map shows the geographic impact of Xiao-E Yan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiao-E Yan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiao-E Yan more than expected).

Fields of papers citing papers by Xiao-E Yan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiao-E Yan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiao-E Yan. The network helps show where Xiao-E Yan may publish in the future.

Co-authorship network of co-authors of Xiao-E Yan

This figure shows the co-authorship network connecting the top 25 collaborators of Xiao-E Yan. A scholar is included among the top collaborators of Xiao-E Yan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiao-E Yan. Xiao-E Yan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Wu, Zhenhua, Xueyan Liu, Xiao-E Yan, et al.. (2025). Discovery of Potent and Selective Pyrrolo[2,3-d]pyrimidine Derivatives as Fourth-Generation EGFR Inhibitors Targeting Triple Mutations. Journal of Medicinal Chemistry. 68(18). 19205–19228.
2.
Yan, Xiao-E, Pelin Ayaz, Sujie Zhu, et al.. (2020). Structural Basis of AZD9291 Selectivity for EGFR T790M. Journal of Medicinal Chemistry. 63(15). 8502–8511. 84 indexed citations
4.
Zhu, Sujie, Peng Zhao, Jiao Yang, et al.. (2018). Structural insights into drug development strategy targeting EGFR T790M/C797S. Oncotarget. 9(17). 13652–13665. 31 indexed citations
5.
Kong, Lulu, et al.. (2017). Structural pharmacological studies on EGFR T790M/C797S. Biochemical and Biophysical Research Communications. 488(2). 266–272. 36 indexed citations
6.
Yan, Xiao-E, Sujie Zhu, Ling Liang, et al.. (2017). Structural basis of mutant-selectivity and drug-resistance related to CO-1686. Oncotarget. 8(32). 53508–53517. 31 indexed citations
8.
Hu, Chen, Aoli Wang, Hong Wu, et al.. (2017). Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode. Oncotarget. 8(11). 18359–18372. 17 indexed citations
9.
Yu, Lei, Minhao Huang, Tianfeng Xu, et al.. (2016). A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFRL858R/T790M mutant with improved pharmacokinetic properties. European Journal of Medicinal Chemistry. 126. 1107–1117. 36 indexed citations
10.
Liang, Ling, Xiao-E Yan, Yuxin Yin, & Cai‐Hong Yun. (2016). Structural and biochemical studies of the PDGFRA kinase domain. Biochemical and Biophysical Research Communications. 477(4). 667–672. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026